{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:54Z","timestamp":1790108814855,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cmi.2023.03.020","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T21:58:03Z","timestamp":1679522283000},"page":"1144-1149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients"],"prefix":"10.1016","volume":"29","author":[{"given":"Raymund R.","family":"Razonable","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.03.020_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American society of transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2023.03.020_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib3","first-page":"840","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","author":"Arthurs","year":"200846","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib4","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2023.03.020_bib5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.cmi.2023.03.020_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2023.03.020_bib9","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2023.03.020_bib10","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1128\/AAC.44.10.2811-2815.2000","article-title":"Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients","volume":"44","author":"Pescovitz","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.03.020_bib11","first-page":"31","article-title":"Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients","volume":"1","author":"Pescovitz","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2165\/00003088-200544050-00003","article-title":"Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients","volume":"44","author":"Wiltshire","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2023.03.020_bib13","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/01.TP.0000164512.99703.AD","article-title":"Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients","volume":"79","author":"Wiltshire","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2023.03.020_bib14","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1086\/444398","article-title":"A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients","volume":"192","author":"Humar","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib15","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2009.02617.x","article-title":"Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients","volume":"9","author":"Asberg","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2023.03.020_bib16","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/cid\/cit096","article-title":"Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients","volume":"56","author":"Razonable","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2023.03.020_bib18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/MOT.0000000000000541","article-title":"Drug-resistant cytomegalovirus: clinical implications of specific mutations","volume":"23","author":"Razonable","year":"2018","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.cmi.2023.03.020_bib19","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2023.03.020_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","article-title":"Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients","volume":"12","author":"Avery","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cmi.2023.03.020_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","article-title":"Maribavir: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2023.03.020_bib24","doi-asserted-by":"crossref","first-page":"e02337","DOI":"10.1128\/AAC.02337-18","article-title":"Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.03.020_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/TP.0000000000002785","article-title":"Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients","volume":"104","author":"Phoompoung","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2023.03.020_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib27","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.03.020_bib28","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2147\/IDR.S180908","article-title":"Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review","volume":"12","author":"El Helou","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cmi.2023.03.020_bib29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2023.03.020_bib30","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/ajt.14347","article-title":"An interventional study using cell-mediated immunity to personalize therapy for cytomegalovirus infection after transplantation","volume":"17","author":"Kumar","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2023.03.020_bib31","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/TP.0000000000002396","article-title":"Clinical correlation of cytomegalovirus infection with CMV-specific CD8+ T-cell immune competence score and lymphocyte subsets in solid organ transplant recipients","volume":"103","author":"Meesing","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.cmi.2023.03.020_bib32","doi-asserted-by":"crossref","first-page":"ofy230","DOI":"10.1093\/ofid\/ofy230","article-title":"Absolute lymphocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplantation","volume":"5","author":"Meesing","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.020_bib34","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/ajt.17147","article-title":"A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients","volume":"22","author":"Azar","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cmi.2023.03.020_bib35","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/cid\/ciy295","article-title":"Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"67","author":"Gardiner","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:34:12Z","timestamp":1761118452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23001362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1198743X23001362"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.03.020","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}